Francisco J LÃ³pez-Soriano

List of Publications by Year
in descending order

174	9,290	28274 55	48315 88
papers	citations	h-index	g-index

178	178	178	7832
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lack of Synergy Between Î²-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. OncoTargets and Therapy, 2021, Volume 14, 1953-1959.	2.0	1
2	Differential structural features in soleus and gastrocnemius of carnitineâ€treated cancer cachectic rats. Journal of Cellular Physiology, 2020, 235, 526-537.	4.1	10
3	A small Cretaceous crocodyliform in a dinosaur nesting ground and the origin of sebecids. Scientific Reports, 2020, 10, 15293.	3.3	18
4	The animal cachexia score (ACASCO). Animal Models and Experimental Medicine, 2019, 2, 201-209.	3.3	9
5	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	2.4	50
6	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	9.6	191
7	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie, 2018, 149, 79-91.	2.6	39
8	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. JCSM Rapid Communications, 2018, 1, 1-15.	1.6	3
9	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	5
10	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Frontiers in Physiology, 2017, 8, 92.	2.8	46
11	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. Frontiers in Physiology, 2017, 8, 184.	2.8	17
12	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20
13	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
14	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
15	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56
16	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43
17	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
18	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78

#	Article	IF	Citations
19	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44
20	A differential pattern of gene expression in skeletal muscle of tumorâ€bearing rats reveals dysregulation of excitationâ€"contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
21	A revision of the first Asteropyginae (Trilobita; Devonian). Geobios, 2014, 47, 281-289.	1.4	4
22	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
23	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
24	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
25	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83
26	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. International Journal of Oncology, 2013, 43, 886-894.	3.3	79
27	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 2013, 54, 3045-3051.	4.2	17
28	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology Letters, 2012, 3, 185-189.	1.8	31
29	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	7.3	115
30	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. E-SPEN Journal, 2012, 7, e135-e138.	0.5	3
31	Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutrition and Metabolism, 2012, 9, 76.	3.0	18
32	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clinical Nutrition, 2012, 31, 889-895.	5.0	37
33	Counteracting Inflammation: A Promising Therapy in Cachexia. Critical Reviews in Oncogenesis, 2012, 17, 253-262.	0.4	59
34	Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 73-76.	7.3	102
35	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	6.4	105
36	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Experimental and Therapeutic Medicine, 2011, 2, 731-735.	1.8	16

#	Article	IF	Citations
37	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. Obesity, 2011, 19, 362-369.	3.0	80
38	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. Clinical Nutrition, 2011, 30, 33-37.	5.0	10
39	Anti-inflammatory therapies in cancer cachexia. European Journal of Pharmacology, 2011, 668, S81-S86.	3.5	63
40	Sirtuin 1 in skeletal muscle of cachectic tumourâ€bearing rats: a role in impaired regeneration?. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 57-62.	7.3	22
41	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 87-93.	7.3	138
42	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 95-104.	7.3	72
43	Interleukinâ€15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. Lipids, 2011, 46, 1033-1042.	1.7	25
44	Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle and Nerve, 2011, 43, 268-273.	2.2	5
45	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16
46	Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 275-280.	1.1	0
47	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncology Reports, 2011, 25, 189-93.	2.6	33
48	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition, 2010, 29, 733-737.	5.0	27
49	Patterns of gene expression in muscle and fat in tumorâ€bearing rats: Effects of CRF2R agonist on cachexia. Muscle and Nerve, 2010, 42, 936-949.	2.2	5
50	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants and Redox Signaling, 2010, 12, 365-380.	5.4	71
51	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discovery Today, 2009, 14, 208-213.	6.4	61
52	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Letters, 2009, 583, 350-356.	2.8	33
53	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
54	The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 263-268.	1.3	162

#	Article	IF	Citations
55	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. International Journal of Molecular Medicine, 2009, 24, 453-8.	4.0	23
56	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
57	Effects of ILâ€15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
58	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
59	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
60	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of Î²2-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43
61	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
62	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
63	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
64	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
65	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
66	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58
67	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29
68	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
69	Cancer Cachexia and Fat Metabolism. , 2006, , 459-466.		2
70	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
71	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79
72	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Letters, 2006, 580, 691-696.	2.8	26

#	Article	IF	Citations
73	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 253-258.	2.4	16
74	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
75	Cytokines as Mediators and Targets for Cancer Cachexia. Cancer Treatment and Research, 2006, 130, 199-217.	0.5	50
76	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	1.8	149
77	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005, 21, 977-985.	2.4	86
78	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews, 2005, 25, 49-65.	10.5	162
79	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. ChemInform, 2005, 36, no.	0.0	1
80	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. International Journal of Biochemistry and Cell Biology, 2005, 37, 1084-1104.	2.8	144
81	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 1609-1619.	2.8	38
82	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 2036-2046.	2.8	89
83	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. FEBS Letters, 2005, 579, 717-722.	2.8	48
84	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
85	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
86	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
87	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
88	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
89	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
90	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95

#	Article	IF	Citations
91	The systemic inflammatory response is involved in the regulation of K+channel expression in brain via TNF-Î±-dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26
92	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
93	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
94	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
95	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
96	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102
97	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
98	Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	114
99	Sepsis induces DNA fragmentation in rat skeletal muscle. European Cytokine Network, 2003, 14, 256-9.	2.0	12
100	The role of uncoupling proteins in pathophysiological states. Biochemical and Biophysical Research Communications, 2002, 293, 1145-1152.	2.1	90
101	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
102	TNF-Î± modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Letters, 2002, 175, 181-185.	7.2	33
103	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2002, 188, 53-58.	7.2	1
104	Tumor necrosis factor-Î± exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 66-72.	4.1	55
105	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. Journal of Cellular Physiology, 2002, 191, 283-289.	4.1	38
106	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
107	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
108	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-Î±?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1499, 249-256.	4.1	23

#	Article	IF	Citations
109	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
110	Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sciences, 2001, 69, 1345-1361.	4.3	21
111	Increased muscle ubiquitin mRNA levels in gastric cancer patients. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R1518-R1523.	1.8	123
112	Cancer cachexia: A therapeutic approach. Medicinal Research Reviews, 2001, 21, 83-101.	10.5	75
113	Hepatic Transport of Gluconeogenic Substrates During Tumor Growth in the Rat. Cancer Investigation, 2001, 19, 248-255.	1.3	0
114	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Journal of Cellular Physiology, 2000, 184, 380-384.	4.1	60
115	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
116	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
117	Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochimica Et Biophysica Acta - General Subjects, 2000, 1475, 5-9.	2.4	31
118	Mechanism for the increased skeletal muscle protein degradation in the obese zucker rat. Journal of Nutritional Biochemistry, 1999, 10, 244-248.	4.2	16
119	The role of cytokines in cancer cachexia. , 1999, 19, 223-248.		183
120	Leptin and tumor growth in rats. , 1999, 81, 726-729.		41
121	Leptin administration to lactating rats is unable to induce changes in lipid metabolism in white adipose tissue or mammary gland. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 84, 93-97.	1.1	4
122	Resveratrol, a Natural Product Present in Wine, Decreases Tumour Growth in a Rat Tumour Model. Biochemical and Biophysical Research Communications, 1999, 254, 739-743.	2.1	246
123	Leptin levels and gene expression during the perinatal phase in the rat. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 81, 95-100.	1.1	5
124	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology, 1998, 142, 183-189.	3.2	104
125	Tumour necrosis factor-Î± does not cross the rat placenta. Cancer Letters, 1998, 128, 101-104.	7.2	14
126	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Letters, 1998, 130, 19-27.	7.2	69

#	Article	IF	Citations
127	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
128	Short-term effects of leptin on lipid metabolism in the rat. FEBS Letters, 1998, 431, 371-374.	2.8	27
129	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64
130	In the rat, tumor necrosis factor Î± administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
131	Catabolic proinflammatory cytokines. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 245-251.	2.5	61
132	Tumor Growth Influences Skeletal Muscle Protein Turnover in the Pregnant Rat. Pediatric Research, 1998, 43, 250-255.	2.3	3
133	Controversy in Basic Sciences Is TNF Really Involved in Cachexia?. Cancer Investigation, 1997, 15, 47-54.	1.3	24
134	TNF Can Directly Induce the Expression of Ubiquitin-Dependent Proteolytic System in Rat Soleus Muscles. Biochemical and Biophysical Research Communications, 1997, 230, 238-241.	2.1	159
135	TNF and pregnancy: the paradigm of a complex interaction. Cytokine and Growth Factor Reviews, 1997, 8, 181-188.	7.2	46
136	Neutral amino acid transport in placental plasma membrane vesicles in the late pregnant rat: Evidence for a B0-like transport system. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1997, 71, 85-90.	1.1	13
137	Lipid metabolism in tumour-bearing mice:. Molecular and Cellular Endocrinology, 1997, 132, 93-99.	3.2	27
138	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. Cancer Letters, 1997, 116, 159-165.	7.2	11
139	Comparative effects of Î²2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Letters, 1997, 115, 113-118.	7.2	44
140	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
141	The Increased Skeletal Muscle Protein Turnover of the Streptozotozin Diabetic Rat Is Associated with High Concentrations of Branched-Chain Amino Acids. Biochemical and Molecular Medicine, 1997, 61, 87-94.	1.4	44
142	Lipogenesis in rat tissues following carbohydrate refeeding: spleen lipogenesis is modulated by insulin. Molecular and Cellular Biochemistry, 1997, 175, 149-152.	3.1	2
143	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends in Pharmacological Sciences, 1996, 17, 223-226.	8.7	67
144	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Letters, 1996, 99, 7-14.	7.2	32

#	Article	IF	Citations
145	Anti-TNF Treatment Reverts Increased Muscle Ubiquitin Gene Expression in Tumour-Bearing Rats. Biochemical and Biophysical Research Communications, 1996, 221, 653-655.	2.1	69
146	Î±-Adrenergic receptors may contribute to the hypertriglyceridemia associated with tumour growth. Cancer Letters, 1996, 110, 213-216.	7.2	3
147	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Molecular and Cellular Biochemistry, 1996, 165, 17-23.	3.1	18
148	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. Biochemical Society Transactions, 1995, 23, 492S-492S.	3.4	2
149	TNF and AIDS: Two sides of the same coin?. Medicinal Research Reviews, 1995, 15, 533-546.	10.5	10
150	Muscle wasting associated with cancer cachexia is linked to an important activation of the atp-dependent ubiquitin-mediated proteolysis. International Journal of Cancer, 1995, 61, 138-141.	5.1	101
151	Metabolic effects of tumour necrosis factor-Î± on rat brown adipose tissue. Molecular and Cellular Biochemistry, 1995, 143, 113-118.	3.1	10
152	Lipopolysaccharide (LPS) increases thein vivo oxidation of branched-chain amino acids in the rat: A cytokine-mediated effect. Molecular and Cellular Biochemistry, 1995, 148, 9-15.	3.1	20
153	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Letters, 1995, 91, 73-78.	7.2	24
154	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Letters, 1995, 97, 25-32.	7.2	21
155	The effects of tumour growth on circulating amino acids in the late pregnant rat. Cancer Letters, 1995, 88, 21-25.	7.2	1
156	The effects of tumour necrosis factor-Î± on circulating amino acids in the pregnant rat. Cancer Letters, 1994, 79, 27-32.	7.2	3
157	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Letters, 1994, 76, 1-4.	7.2	48
158	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 1994, 87, 123-130.	7.2	9
159	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Letters, 1994, 338, 311-318.	2.8	120
160	Anti-Tumour Necrosis Factor-Î± Treatment Interferes with Changes in Lipid Metabolism in a Tumour Cachexia Model. Clinical Science, 1994, 87, 349-355.	4.3	70
161	Tumour necrosis factor-Î± increases the ubiquitinization of rat skeletal muscle proteins. FEBS Letters, 1993, 323, 211-214.	2.8	125
162	Tumour necrosis factor-Î± alters the blood compartmentation of amino acids in the rat. Cancer Letters, 1993, 72, 71-76.	7.2	4

#	Article	IF	Citations
163	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. Cancer Letters, 1993, 72, 169-173.	7.2	13
164	The enzymatic activities of branched-chain amino acid catabolism in tumour-bearing rats. Cancer Letters, 1992, 61, 239-242.	7.2	8
165	Metabolism of glucose in isolated intestinal cells from obese zucker rats. Nutrition Research, 1992, 12, 949-954.	2.9	0
166	Amino acid metabolism in several tissues of the obese Zucker rat as indicated by the tissue accumulation of Î±-amino[1-14C]isobutyrate. Molecular and Cellular Biochemistry, 1992, 110, 155-159.	3.1	2
167	The role of insulin in the intestinal absorption of glucose in the rat. International Journal of Biochemistry & Cell Biology, 1992, 24, 631-636.	0.5	3
168	The role of cytokines in muscle wasting: Its relation with cancer cachexia. Medicinal Research Reviews, 1992, 12, 637-652.	10.5	77
169	Glucose handling by hepatocytes from obese Zucker rats. Bioscience Reports, 1991, 11, 285-292.	2.4	2
170	Intestinal amino acid transport: An overview. International Journal of Biochemistry & Cell Biology, 1990, 22, 931-937.	0.5	16
171	In vitro alanine utilization by rat interscapular brown adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 1990, 1036, 6-10.	2.4	3
172	Effects of tumour necrosis factor on hepatic amino acid uptake. Biochemical Society Transactions, 1989, 17, 1045-1046.	3.4	3
173	Oxidation of branched-chain amino acids in tumour-bearing rats. Biochemical Society Transactions, 1989, 17, 1044-1045.	3.4	6
174	The appearance of 2,3-butanediol in the chronic ethanol treated pregnant rat. Drug and Alcohol Dependence, 1986, 18, 335-339.	3.2	2